JP2017516775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516775A5 JP2017516775A5 JP2016568918A JP2016568918A JP2017516775A5 JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5 JP 2016568918 A JP2016568918 A JP 2016568918A JP 2016568918 A JP2016568918 A JP 2016568918A JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- treatment
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 6
- 230000000340 anti-metabolite Effects 0.000 claims 6
- 229940100197 antimetabolite Drugs 0.000 claims 6
- 239000002256 antimetabolite Substances 0.000 claims 6
- 238000009175 antibody therapy Methods 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MKLKAQMPKHNQPR-NSHDSACASA-N C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O Chemical compound C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O MKLKAQMPKHNQPR-NSHDSACASA-N 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096807A JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462002366P | 2014-05-23 | 2014-05-23 | |
| US62/002,366 | 2014-05-23 | ||
| US201562150004P | 2015-04-20 | 2015-04-20 | |
| US62/150,004 | 2015-04-20 | ||
| PCT/US2015/031931 WO2015179615A1 (en) | 2014-05-23 | 2015-05-21 | Combination therapies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Division JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516775A JP2017516775A (ja) | 2017-06-22 |
| JP2017516775A5 true JP2017516775A5 (cg-RX-API-DMAC7.html) | 2018-06-28 |
| JP6787792B2 JP6787792B2 (ja) | 2020-11-18 |
Family
ID=53277114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568918A Active JP6787792B2 (ja) | 2014-05-23 | 2015-05-21 | がんの処置のための併用治療 |
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170182003A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4656246A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6787792B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102535283B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN106572993B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015264102C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2949961C (cg-RX-API-DMAC7.html) |
| IL (1) | IL249065A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA39906A (cg-RX-API-DMAC7.html) |
| MX (1) | MX393818B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2708374C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201609770TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015179615A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179615A1 (en) * | 2014-05-23 | 2015-11-26 | Eisai R&D Management Co., Ltd | Combination therapies for the treatment of cancer |
| CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| HUE057799T2 (hu) * | 2016-07-07 | 2022-06-28 | Ono Pharmaceutical Co | EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció |
| WO2018037595A1 (ja) * | 2016-08-26 | 2018-03-01 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
| PE20191353A1 (es) | 2016-10-14 | 2019-10-01 | Prec Biosciences Inc | Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| US10617667B2 (en) * | 2017-11-01 | 2020-04-14 | Ono Pharmaceutical Co., Ltd. | Method for treating brain tumors |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| AU2019214193B2 (en) * | 2018-02-05 | 2022-06-16 | Foshan Ionova Biotherapeutics Co., Inc. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| AU2019223182B2 (en) | 2018-02-26 | 2021-08-19 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as HBV replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CN112292128A (zh) * | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020081979A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Low dose radiation conditioning for immunotherapy |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| EP3889134B1 (en) * | 2019-01-22 | 2024-09-25 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020231201B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US20220233694A1 (en) * | 2019-05-31 | 2022-07-28 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| MX2022003658A (es) | 2019-09-30 | 2022-04-25 | Gilead Sciences Inc | Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb. |
| CN114729051A (zh) * | 2019-11-21 | 2022-07-08 | 百济神州(北京)生物科技有限公司 | 使用抗ox40抗体与放射组合治疗癌症的方法 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| US20230125494A1 (en) * | 2020-03-04 | 2023-04-27 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Synthesis of novel ep4 antagonist and use in cancer and inflammation |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2022037601A1 (zh) * | 2020-08-18 | 2022-02-24 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| WO2022161418A1 (zh) * | 2021-01-28 | 2022-08-04 | 深圳晶泰科技有限公司 | 吡唑酰胺衍生物及其制备方法和应用 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| US20240368088A1 (en) * | 2021-09-03 | 2024-11-07 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Ep4 antagonist compound as well as salt, polymorph and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1691801A4 (en) * | 2003-12-08 | 2009-12-09 | Univ Arizona State | SYNERGISTIC ANTI-CANCER COMPOSITIONS |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| JP5259592B2 (ja) * | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN102421429B (zh) * | 2009-04-22 | 2016-08-17 | 拉夸里亚创药株式会社 | 癌症治疗用选择性ep4受体拮抗物质 |
| AU2010303149B2 (en) | 2009-09-30 | 2016-08-04 | Board Of Regents, The University Of Texas System | Combination immunotherapy for the treatment of cancer |
| JP5956448B2 (ja) * | 2010-09-21 | 2016-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| US20150004175A1 (en) * | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| WO2015179615A1 (en) | 2014-05-23 | 2015-11-26 | Eisai R&D Management Co., Ltd | Combination therapies for the treatment of cancer |
-
2015
- 2015-05-21 WO PCT/US2015/031931 patent/WO2015179615A1/en not_active Ceased
- 2015-05-21 RU RU2016150650A patent/RU2708374C2/ru active
- 2015-05-21 EP EP25174070.0A patent/EP4656246A2/en active Pending
- 2015-05-21 CA CA2949961A patent/CA2949961C/en active Active
- 2015-05-21 US US15/312,980 patent/US20170182003A1/en not_active Abandoned
- 2015-05-21 JP JP2016568918A patent/JP6787792B2/ja active Active
- 2015-05-21 SG SG11201609770TA patent/SG11201609770TA/en unknown
- 2015-05-21 MA MA039906A patent/MA39906A/fr unknown
- 2015-05-21 CN CN201580039416.7A patent/CN106572993B/zh active Active
- 2015-05-21 KR KR1020167035808A patent/KR102535283B1/ko active Active
- 2015-05-21 AU AU2015264102A patent/AU2015264102C1/en active Active
- 2015-05-21 CN CN201910572217.2A patent/CN110354266A/zh active Pending
- 2015-05-21 EP EP15726847.5A patent/EP3134085B1/en active Active
- 2015-05-21 MX MX2016015363A patent/MX393818B/es unknown
-
2016
- 2016-11-20 IL IL249065A patent/IL249065A0/en active IP Right Grant
-
2020
- 2020-06-03 JP JP2020096807A patent/JP7562296B2/ja active Active
-
2021
- 2021-11-17 US US17/528,510 patent/US11707448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A5 (cg-RX-API-DMAC7.html) | ||
| JP2016533366A5 (cg-RX-API-DMAC7.html) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2017517506A5 (cg-RX-API-DMAC7.html) | ||
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2016501221A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532047A5 (cg-RX-API-DMAC7.html) | ||
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| JP2019523214A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522858A5 (cg-RX-API-DMAC7.html) | ||
| JP2017510661A5 (cg-RX-API-DMAC7.html) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2015500225A5 (cg-RX-API-DMAC7.html) | ||
| JP2016041733A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536286A5 (cg-RX-API-DMAC7.html) | ||
| WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
| CY1116847T1 (el) | Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 | |
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2019533651A5 (cg-RX-API-DMAC7.html) | ||
| MX385704B (es) | Derivado de heteroarilo o su sal farmacéuticamente aceptable, su método de preparación y composición farmacéutica para la prevención o tratamiento de enfermedades asociadas con pi3 cinasas que contiene el mismo como ingrediente activo. | |
| JP2015502926A5 (cg-RX-API-DMAC7.html) | ||
| JP2019511550A5 (cg-RX-API-DMAC7.html) | ||
| JP2016519107A5 (cg-RX-API-DMAC7.html) |